Inclusion Criteria:  Fluent in English ASD diagnosis confirmed by the clinician/clinical team, and IQ> or =70 Able to participate in the informed consent process, provide voluntary informed consent and provide a spontaneous narrative description of the key elements of the study Clinical stability: determined by a physician, no switch of psychotropic medications or increase in dosage in the last 30 days; no change in other therapeutic interventions in last 30 days BDI-II score ≥21 that is sustained over a lead-in period of two weeks Global Assessment of Function (GAF) scores (≤60) that is sustained over a lead-in period of two weeks AND/OR VABS-III below adequate functioning at baseline assessment.  Exclusion Criteria:  A history of a DSM-5 substance use disorder (other than tobacco) within the past six months; or a positive baseline urine drug screen Significantly debilitating medical or neurologic illness, or acute or unstable medical illnesses as determined by study physician Metal implants or a pace-maker, claustrophobia that would preclude the MRI scan Actively suicidal (i.e., suicidal ideation with plan and intent) or high risk for suicide as assessed by a study psychiatrist History of seizures Taking benzodiazepines at a dose greater or equal to 2mg Lorazepam or any anticonvulsant medication Prior rTMS treatment Pregnancy